After seeing its market cap soar on the prospects of a highly-touted Covid-19 vaccine, Inovio saw its share price $INO led to slaughter on Monday after announcing that the FDA is forcing investigators to hit the brakes on a planned Phase II/III study. The agency has some questions for Inovio

There has been a devastating effect of the coronavirus (COVID-19) pandemic on the early stage research space through the suspension of over 9,000, and cancelling of over 1,000, clinical trials in the UK.

The World Health Organization's warning comes as the number of deaths is nearing one million.

As the SARS-CoV-2 pandemic is rapidly progressing, the need for the development of an effective vaccine is critical. A promising approach for vaccine development is to generate, through codon pair deoptimization, an attenuated virus. This approach carries the advantage that it only requires limited …

Researchers warn that vaccines could stumble on safety trials, be fast-tracked because of politics or fail to meet the public’s expectations.

The on-going coronavirus disease 19 (COVID-19) pandemic has caused a very high number of infections and deaths around the globe. The absence of vaccine/drugs to counter COVID-19 has scrambled scientific communities to repurpose available medicines/vaccines. As the virus is known to mutate, using the whole genome sequences, the transmission dynamics and molecular evolutionary models were evaluated...

But some things are improving, and it will not go on for ever

• The most variable virus gene encodes the spike (S) protein that mediates virus attachment to and entry into cells, and is the target of neutralising antibodies and a robust T cell response. A D614G mutation in the S1 subunit of the S protein possibly enhances virus transmission and is now dominant in virus strains...